VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Andrea NecchiGiuseppe BasileEwan A GibbDaniele RaggiGiuseppina CalaresoTiago Costa de PaduaDamiano PatanèEmanuele CrupiChiara MercinelliAntonio CigliolaValentina TateoPatrizia GiannatempoMarco MoschiniAlberto BrigantiFrancesco MontorsiAntonella MessinaJeffrey S RossDean PavlickFrancesco De CobelliGiorgio BrembillaPublished in: BJU international (2023)
Post-pembrolizumab VI-RADS scores are strongly associated with pathological downstaging and survival. VI-RADS scores were also characterized by distinct biomarker features. These results indicate that the VI-RADS is emerging as an important tool for designing next-generation trials for MIBC.